On July 17, 2026 IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, reported three abstract presentations at the 2026 European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) meeting, taking place on October 23-27 in Madrid, Spain. The presentations will feature data updates from across IDEAYA’s clinical pipeline, including multiple ongoing trials of darovasertib in uveal melanoma, including the registrational Phase 2/3 OptimUM-02 trial in HLA*A2:01-negative metastatic UM (mUM), the Phase 2 OptimUM-01 trial in HLA*A2:01-positive mUM, and the Phase 2 OptimUM-09 trial in the neoadjuvant setting of primary uveal melanoma. IDEAYA’s partner, Hengrui Pharma, will also present clinical trial results from their Phase 1 study of IDE849 (SHR-4849) being conducted in China in patients with small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re excited to showcase the breadth of our pipeline progress at this year’s ESMO (Free ESMO Whitepaper) Congress. Additional data from our ongoing trials in both metastatic and neoadjuvant uveal melanoma, namely OptimUM-02, OptimUM-01 and OptimUM-09, bolster our conviction in the potential of darovasertib to become an important new treatment option across the uveal melanoma patient journey. We also hope to highlight the potential best-in-class profile of IDE849, our Phase 1 DLL3 TOP1 ADC, in SCLC and NECs, where monotherapy and combination trials are ongoing and the program’s first registrational trial is targeted to initiate by year-end by partner Hengrui in China and in our regions, including the US," said Dr. Darrin Beaupre, Chief Medical Officer, IDEAYA Biosciences.
IDEAYA Presentations:
2092P (Poster Presentation); Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study. Presenting Author – Mark Shackleton, MBBS, PhD, FRACP, Department of Oncology, Alfred Hospital, and Department of Cancer Medicine, Monash University, Melbourne, Australia
2104P (Poster Presentation); Darovasertib with Crizotinib vs Investigator’s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma (OptimUM-02): A Subgroup Analysis. Presenting Author – Sophie Piperno-Neumann, MD, PhD, Institute Curie Research University, Paris, France
2086P (Poster Presentation); Darovasertib and Crizotinib for HLA-A*02–Positive Metastatic Uveal Melanoma: Results from the Phase 2 OptimUM-01 Study. Presenting Author – Meredith McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, Tennessee, United States
Hengrui Presentation:
3815P (Poster Presentation); SHR-4849 (IDE849), an ADC targeting delta-like ligand 3 (DLL3), in relapsed small cell lung carcinoma (SCLC) and other neuroendocrine carcinomas (NECs): long-term results from the Phase 1 study. Presenting Author – Haifeng Liu, PhD, Professor, Clinical Research Ward, Jilin Cancer Hospital, Changchun, China
(Press release, Ideaya Biosciences, JUL 17, 2026, View Source [SID1234669291])